ArticleEndocrinology and metabolism (Seoul, Korea)2015
Apolipoprotein B Is Related to Metabolic Syndrome Independently of Low Density Lipoprotein Cholesterol in Patients with Type 2 Diabetes.
Article in Endocrinology and metabolism (Seoul, Korea), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Association of apolipoproteins and lipoprotein(a) with metabolic syndrome: a systematic review and meta-analysis.Lipids in health and disease · 2023Pooled it
- Beyond eGFR and Albuminuria: Biological Pathways and Multiomics in Cardiovascular-Kidney-Metabolic Disease.Kidney international reports · 2026Review
- Lipoprotein trajectories from prediabetes to type 2 diabetes with complications: a Chinese population-specific formula for sdLDL-C estimation.Lipids in health and disease · 2025Article
- Lipid profiles in major depression, both with and without metabolic syndrome: associations with suicidal behaviors and neuroticism.BMC psychiatry · 2025Article
- ApoB100 and Atherosclerosis: What's New in the 21st Century?Metabolites · 2024Review
- Current Data and New Insights into the Genetic Factors of Atherogenic Dyslipidemia Associated with Metabolic Syndrome.Diagnostics (Basel, Switzerland) · 2023Review
- Genetics of Cholesterol-Related Genes in Metabolic Syndrome: A Review of Current Evidence.Biomedicines · 2022Review
- Circulating lipids and breast cancer prognosis in the Malmö diet and cancer study.Breast cancer research and treatment · 2022Article
- Cardiovascular Biomarkers of Obesity and Overlap With Cardiometabolic Dysfunction.Journal of the American Heart Association · 2021Article
- Prevalence of ApoB100 rs693 gene polymorphism in metabolic syndrome among female students at King Abdulaziz University.Saudi journal of biological sciences · 2021Article
- Lipoprotein A, combined with alanine aminotransferase and aspartate aminotransferase, contributes to predicting the occurrence of NASH: a cross-sectional study.Lipids in health and disease · 2020Article
- Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol.Lipids in health and disease · 2020Article
- Menopause-Associated Lipid Metabolic Disorders and Foods Beneficial for Postmenopausal Women.Nutrients · 2020Review
- Novel and traditional lipid profiles in Metabolic Syndrome reveal a high atherogenicity.Scientific reports · 2019Article
- Association of Serum Apolipoprotein B with the Increased Risk of Diabetes in Korean Men.Clinical nutrition research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIncreased low density lipoprotein cholesterol (LDL-C) level and the presence of metabolic syndrome (MetS) are important risk factors for cardiovascular disease (CVD) in type 2 diabetes mellitus (T2DM). Recent studies demonstrated apolipoprotein B (apoB), a protein mainly located in LDL-C, was an independent predictor of the development of CVD especially in patients with T2DM. The aim of this study was to investigate the relationship between apoB and MetS in T2DM patients.
methodsWe analyzed 912 patients with T2DM. Fasting blood samples were taken for glycated hemoglobin, high-sensitivity C-reactive protein, total cholesterol, triglyceride (TG), high density lipoprotein cholesterol, LDL-C, and apoB. MetS was defined by the modified National Cholesterol Education Program Adult Treatment Panel III criteria. We performed a hierarchical regression analysis with apoB as the dependent variable. Age, sex, the number of components of MetS and LDL-C were entered at model 1, the use of lipid-lowering medications at model 2, and the individual components of MetS were added at model 3.
resultsSeventy percent of total subjects had MetS. ApoB level was higher in subjects with than those without MetS (104.5±53.3 mg/dL vs. 87.7±33.7 mg/dL, P<0.01) even after adjusting for LDL-C. ApoB and LDL-C were positively correlated to the number of MetS components. The hierarchical regression analysis showed that the increasing number of MetS components was associated with higher level of apoB at step 1 and step 2 (β=0.120, P<0.001 and β=0.110, P<0.001, respectively). At step 3, TG (β=0.116, P<0.001) and systolic blood pressure (β=0.099, P<0.05) were found to significantly contribute to apoB.
conclusionIn patients with T2DM, apoB is significantly related to MetS independently of LDL-C level. Of the components of MetS, TG, and systolic blood pressure appeared to be determinants of apoB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.